Adverse events following immunization with bivalent oral poliovirus vaccine in Jiangsu, China
- 8 July 2021
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (12), 4831-4838
- https://doi.org/10.1111/bcp.14976
Abstract
Aims The bivalent oral poliovirus vaccine (bOPV; Sabin types 1 and 3) replaced the trivalent OPV (Sabin types 1, 2 and 3) globally in April 2016. A routine schedule of 1 dose of inactivated poliovirus vaccine and 3 subsequent doses of bOPV was implemented in Jiangsu simultaneously. The schedule was changed to 2 inactivated poliovirus vaccines + 2 bOPV on 1 September 2019. Although OPV type 2 has been removed, challenges persist because of adverse events following immunization (AEFIs) with bOPV. Therefore, we analysed and evaluated the safety profile of bOPV administered in children based on passive postmarketing AEFI surveillance. Methods We collected all bOPV-related AEFI reports in Jiangsu from the Chinese National AEFI Information System (CNAEFIS) between May 2016 and April 2020. We obtained the administered doses of bOPV from the Jiangsu Provincial Electronic Immunization Registries System. A descriptive analysis was performed. Results In total, 2084 bOPV-related AEFIs were retrieved from the CNAEFIS. The overall reporting rate was 24.16 per 100 000 doses. Most AEFIs were nonserious. The most frequently reported symptoms were fever, rash and gastrointestinal disorders. Only 1.34% of AEFIs were serious, which thrombocytopenic purpura accounted for the largest category. Seventeen serious adverse events, including 2 vaccine-associated paralytic poliomyelitis (VAPP) cases, were considered to be related to bOPV vaccination. The rate of VAPP was 0.2 per million doses. Conclusion AEFI analysis showed that bOPV was well tolerated. The events most frequently reported were nonserious. However, bOPV can still cause VAPP. Attention should be given to risks related to bOPV.This publication has 21 references indexed in Scilit:
- Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine — Worldwide, 2016Morbidity and Mortality Weekly Report (MMWR), 2016
- Update on Vaccine-Derived Polioviruses — Worldwide, January 2015–May 2016Morbidity and Mortality Weekly Report (MMWR), 2016
- Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority studyThe Lancet Infectious Diseases, 2015
- Routine surveillance of adverse events following immunization as an important tool to monitor vaccine safetyHuman Vaccines & Immunotherapeutics, 2014
- Vaccine-Associated Paralytic Poliomyelitis: A Review of the Epidemiology and Estimation of the Global BurdenThe Journal of Infectious Diseases, 2014
- Vaccine-Associated Paralytic Poliomyelitis in the Postelimination Era in Latin America and the Caribbean, 1992–2011The Journal of Infectious Diseases, 2014
- Adverse events following immunization with oral poliovirus in Kinshasa, Democratic Republic of Congo: preliminary resultsPathogens and Global Health, 2013
- Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitisExpert Review of Vaccines, 2012
- Surveillance for Poliovirus Vaccine Adverse Events, 1991 to 1998: Impact of a Sequential Vaccination Schedule of Inactivated Poliovirus Vaccine Followed by Oral Poliovirus VaccinePEDIATRICS, 2001
- Combination Vaccines: Issues in Evaluation of Effectiveness and SafetyEpidemiologic Reviews, 1999